New research highlights an important consideration for men battling prostate cancer: Taking certain medications together may increase the risk of heart disease.
Prostate cancer, which affects millions of people worldwide, often requires treatment that targets testosterone, the hormone essential for cancer growth.
Two main drug classes are used alone or in combination to manage the disease: androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSIs). These treatments have been shown to be effective in extending survival, but recent studies have shown they can have significant effects on cardiovascular health.
Increased risk of heart attack
A review of 24 clinical trials involving more than 22,000 men ages 63 to 77 revealed that the combination of ADT and ARSIs can double the risk of heart attacks, which can range from high blood pressure to serious conditions requiring hospitalization, such as irregular heartbeats, blood clots, heart attacks and strokes.
Of particular concern are findings showing that use of two specific ARSIs, abiraterone acetate and enzalutamide, increases the risk of serious cardiac events by up to fourfold.
The study analyzed treatments for different stages of prostate cancer, including trials published between 2012 and 2024. It concluded that while enhanced ADT may improve cancer outcomes, the cardiovascular risks should not be overlooked. Experts warn that men considering these treatments should be thoroughly evaluated for existing heart disease and closely monitored during treatment.
Impact of migration
Many of these risks are manageable through lifestyle changes and targeted medical interventions. Measures such as maintaining a heart-healthy diet, exercising regularly and controlling blood pressure can significantly reduce the potential side effects of these treatments.
In some cases, medications such as statins may be prescribed to lower cholesterol levels and reduce the risk of cardiovascular disease.
The findings have prompted expert groups worldwide to reconsider the use of certain ARSI combinations in the treatment of prostate cancer. The focus is now shifting to optimizing treatment to balance cancer inhibition with minimizing cardiovascular harm. Patients and their healthcare professionals are urged to carefully weigh the benefits and risks and tailor treatment plans to their individual health conditions.
As research advances, there will be an increased focus on personalized medicine and comprehensive patient care. By incorporating cardiac health assessments into prostate cancer management strategies, clinicians hope to improve overall outcomes and quality of life for men trying to navigate this challenging diagnosis.
In conclusion, advances in prostate cancer treatment bring new hope, but the dual challenges of cancer control and cardiovascular safety emphasize the need for informed decision-making and careful health management.
